Physician

Farhan Mohammad, M.D.

According to 2025 Medicare claims, Farhan Mohammad, M.D. (NPI: 1184902512) practices hematology/oncology in the Dallas-Plano-Irving, TX market, with the plurality of this provider's patient population coming from Collin, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1811944101; TIN: 752131429) and primary practice location at 75069-1605. Mohammad is affiliated with the UT Southwestern Accountable Care Network (ACO ID: D0211), participating under the REACH model.

Mohammad's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 450 traditional Medicare patients, billed 138,729 HCPCS/CPT codes, and received $2,261,683 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,140 prescription claims across 189 beneficiaries totaling $1,936,121 in drug costs, led by Lenalidomide (Lenalidomide). 2023 DME data shows 33 claims. Open Payments data shows 57 records totaling $1,277. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $7,450 to $2,261,683. Similarly, Part D prescription costs have moved sharply higher in recent years, from $583 to $1,936,121. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	76	81	$7,450
2016	28	49	$3,287
2017	97	156	$12,126
2018	107	715	$15,856
2019	248	60,862	$287,384
2020	259	106,265	$928,576
2021	288	81,134	$1,250,374
2022	326	62,194	$853,809
2023	397	138,609	$2,014,523
2024	450	138,729	$2,261,683

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	19	$583
2016	34	57	$3,207
2017	29	51	$4,290
2018	49	99	$5,823
2019	88	363	$96,204
2020	101	414	$190,863
2021	131	635	$720,038
2022	148	730	$1,388,331
2023	151	735	$915,858
2024	189	1,140	$1,936,121

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	11	$334
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	33	$1,399
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	208	938	$92
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	183	374	$12
80053	Blood test, comprehensive group of blood chemicals	195	765	$10
36415	Insertion of needle into vein for collection of blood sample	218	993	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	217	994	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	28	763	$411,687
Revlimid	Lenalidomide	17	476	$385,715
Lynparza	Olaparib	16	480	$218,030
Mekinist	Trametinib Dimethyl Sulfoxide	12	360	$193,585
Xtandi	Enzalutamide	11	330	$160,807

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	57	$1,277	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Farhan Mohammad, M.D.?

Tedicare shows public-source Medicare data for Farhan Mohammad, M.D. (NPI 1184902512), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Farhan Mohammad, M.D. have ACO affiliation data?

Farhan Mohammad, M.D. is shown with ACO affiliation data for UT Southwestern Accountable Care Network (REACH, ACO ID D0211).

What billing organization is linked to Farhan Mohammad, M.D.?

Farhan Mohammad, M.D. is linked to TEXAS ONCOLOGY PA (billing NPI 1811944101) in the available physician profile data.

Does Farhan Mohammad, M.D. have Open Payments data?

Farhan Mohammad, M.D. has 57 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.